Full history for every metric is available with a Kvantra account
Day One Biopharmaceuticals, Inc. (DAWN)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 131 | 158 | 158 |
| Operating profit | $m | -128 | -128 | |||||
| Net profit | $m | -41 | -71 | -142 | -189 | -95 | -107 | -107 |
| EPS reported | $ | -1.04 | -1.04 | |||||
| Operating cashflow per share | $ | -1.00 | -1.00 | |||||
| Capex per share | $ | 0.00 | 0.04 | |||||
| FCF per share | $ | -1.01 | -1.04 | |||||
| Free cash flow | $m | -104 | -108 | |||||
| Net debt | $m | -441 | -441 | |||||
| Book value equity | $m | 441 | 441 | |||||
| Book value per share | $ | 4.27 | 4.27 | |||||
| Number of shares | m | 103.38 | 103.38 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.18 | 5.04 | |||||
| P/S LTM | x | 6.09 | 14.06 | |||||
| P/FCF LTM | x | -9.26 | -20.68 | |||||
| EV/EBITDA LTM | x | -7.29 | -16.90 | |||||
| EV/Sales LTM | x | 4.86 | 11.28 | |||||
| Earnings Yield LTM | % | -11.14% | -4.82% | |||||
| FCF Yield | % | -10.80% | -4.84% | |||||
| Quality | ||||||||
| ROE | % | -24.33% | -23.43% | |||||
| ROIC | % | -28.03% | -28.03% | |||||
| Operating margin | % | -80.76% | -80.76% | |||||
| Gross margin | % | 89.12% | 89.12% | |||||
| FCF/Sales | % | -65.80% | -68.01% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +20.60% | +20.60% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -37.26 | -38.52 | |||||
| Net Debt/EBITDA | x | 1.84 | 1.84 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -45.78% | -19.83% | |||||
| Net debt/Equity | x | -1.00 | -1.00 | |||||
| Gross debt/equity | x | 0.01 | 0.01 | |||||
Company overview
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Day One Biopharmaceuticals, Inc. (DAWN)
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free